Ipsen SA

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 نوفمبر 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

22 أكتوبر 2024 22:00:00 بحسب Nasdaq GlobeNewswire

Ipsen receives its second Shingo Prize for operational excellence

14 أكتوبر 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 أكتوبر 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

23 سبتمبر 2024 04:13:10 بحسب Nasdaq GlobeNewswire

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

20 سبتمبر 2024 05:57:57 بحسب Nasdaq GlobeNewswire

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

16 سبتمبر 2024 05:45:00 بحسب Nasdaq GlobeNewswire

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

15 سبتمبر 2024 05:45:00 بحسب Nasdaq GlobeNewswire

Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

04 سبتمبر 2024 09:00:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024

13 أغسطس 2024 09:00:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024

06 أغسطس 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

05 أغسطس 2024 09:00:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024

30 يوليو 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases

26 يوليو 2024 03:46:22 بحسب Nasdaq GlobeNewswire

Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)

25 يوليو 2024 05:18:23 بحسب Nasdaq GlobeNewswire

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

24 يوليو 2024 22:00:00 بحسب Nasdaq GlobeNewswire

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

24 يوليو 2024 21:58:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

23 يوليو 2024 09:00:00 بحسب Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

16 يوليو 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

10 يوليو 2024 22:00:00 بحسب Nasdaq GlobeNewswire